Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan

British Journal of Clinical Pharmacology

Volumn 57, Issue 4, 2004, Pages 412-415

  Antila, Saila ^a   Kivikko, Matti ^a   Lehtonen, Lasse ^a,d   Eha, Jaan ^b   Heikkilä, Aira ^a   Pohjanjousi, Pasi ^a   Pentikäinen, Pertti J ^c  

^a ORION CORPORATION   (Finland)

^b Mustamae Hospital   (Estonia)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Calcium sensitizer; Levosimendan; Metabolism; Pharmacokinetics

Indexed keywords

LEVOSIMENDAN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; OR 1855; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HEART FAILURE; HUMAN; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE;

ACETAMIDES; CARDIOTONIC AGENTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; PROTEIN BINDING; PYRIDAZINES;

EID: 1942455382     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2003.02043.x     Document Type: Article

References (7)

1. Sandell E-P, Häyhä M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, Pentikäinen PJ. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995; 26(Suppl 1): S57-S62.
2. Sundberg S, Antila S, Scheinin H, Häyhä M, Virtanen M, Lehtonen L. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther 1998; 36: 629-35.
3. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81-6.
4. Takahashi R, Talukder MAH, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol 2000; 36: 118-25.
5. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002; 43: 43-51.
6. Follath F, Cleland JGF, Just H, Papp JGY, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell E-P, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202.
7. Lilleberg J, Sundberg S, Häyhä M, Akkila J, Nieminen MS. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 267-74.